Conversations in PAH: Global Trends in PH Clinical Trials and Risk Assessment - Activity 2 скачать в хорошем качестве

Conversations in PAH: Global Trends in PH Clinical Trials and Risk Assessment - Activity 2

Global Trends in CTEPH Diagnosis, Treatment and Trials AMA/ANCC/ACPE Activity This AMA/ANCC/ACPE activity features a recorded discussion among three leading pulmonary hypertension (PH) experts and is designed to keep healthcare professionals on top of the most recent clinical findings. New information is constantly being learned about the management of patients with PH. Pulmonary Hypertension Due to Interstitial Lung Disease (PH-ILD) represents a complex condition which now has a recently approved inhaled therapy to improve exercise ability. Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but treatable complication of PE, which is often indistinguishable from pulmonary arterial hypertension (PAH). All patients with PH benefit from intensive, continuous clinical monitoring either in person or remotely to guide escalation of treatments. PH remains a disease with poor outcomes, necessitating early diagnosis and appropriate intervention. Improvements in survival and care depends on improving clinician awareness of the latest research and perspectives. This activity brings cutting-edge research to busy clinicians enabling them to readily keep abreast of emerging published research as it relates to the management of PH. FACULTY Ronald Oudiz, MD, FACP, FACC, FCCP Professor of Medicine David Geffen School of Medicine at UCLA Interim Chief, Division of Cardiology Director, Liu Center for Pulmonary Hypertension Ludquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Steven Nathan, MD Medical Director, Advanced Lung Disease and Transplant Program Inova Fairfax Hospital Nick H. Kim, MD Professor of Medicine Medical Director, Pulmonary Thromboendarterectomy Program Division of Pulmonary, Critical Care and Sleep Medicine University of California, San Diego Review the activity at https://bit.ly/3Jx9H4l and claim AMA, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation. This activity is jointly provided by the University of Nebraska Medical Center, Duquesne University School of Pharmacy and Practice Point Communications. Supported by independent educational grants from United Therapeutics Corporation, Bayer U.S. and Actelion Pharmaceuticals U.S., Inc., A Janssen Pharmaceutical Company of Johnson & Johnson.